Aldeyra Therapeutics, Inc. SEC filings ALDX

Aldeyra Therapeutics, Inc. has 647 filings in SEC EDGAR's recent list, going back to Oct 6, 2005. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Sep 29, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Aldeyra Therapeutics, Inc. SEC filings
Form Description Filed Period
ARS Annual report to shareholders Apr 27, 2026 Dec 31, 2025
10-K Annual report Feb 27, 2026 Dec 31, 2025
ARS Annual report to shareholders Apr 25, 2025 Dec 31, 2024
10-K/A Amended annual report Mar 28, 2025 Dec 31, 2024
10-K Annual report Feb 28, 2025 Dec 31, 2024
ARS Annual report to shareholders Apr 22, 2024 Dec 31, 2023
10-K Annual report Mar 7, 2024 Dec 31, 2023
ARS Annual report to shareholders May 24, 2023 Dec 31, 2022
10-K/A Amended annual report Apr 28, 2023 Dec 31, 2022
10-K Annual report Mar 9, 2023 Dec 31, 2022
10-K Annual report Mar 17, 2022 Dec 31, 2021
10-K Annual report Mar 11, 2021 Dec 31, 2020
10-K Annual report Mar 12, 2020 Dec 31, 2019
10-K Annual report Mar 8, 2019 Dec 31, 2018
10-K Annual report Mar 29, 2018 Dec 31, 2017
10-K Annual report Mar 30, 2017 Dec 31, 2016
10-K Annual report Mar 30, 2016 Dec 31, 2015
10-K Annual report Mar 23, 2015 Dec 31, 2014

Showing 18 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ALDX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Concord, MA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1341235
Former names
Aldexa Therapeutics, Inc. (until Mar 4, 2014); Neuron Systems Inc (until Aug 1, 2008)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.